feedback

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: May 10, 2019
Expires: May 10, 2020
30 minutes to complete

Provided By

Target Audience

This program is intended for endocrinologists and healthcare providers that manage patients with T1DM.

Learning Objectives

  • Explain the relationship between glycemic control and micro/macrovascular complications in patients with T1DM
  • Apply current evidence-based strategies to achieve glycemic control while minimizing common side effects of insulin therapy
  • Discuss the evolving role of SGLT inhibitors with insulin in patients with T1DM

Activity Description

Insulin is the staple of therapy in patients with T1DM; however, sodium-glucose cotransporter (SGLT) inhibitors have been investigated as a potential adjunct therapy to improve glycemic outcomes while minimizing adverse events in these patients. To be best prepared to achieve glycemic goals in patients with T1DM, HCPs must be kept up-to-date on new evidence from the medical literature and clinical practice, including the relationship between glycemic control and micro/macrovascular complications, strategies for achieving effective glycemic control, and recent data on the use of SGLT inhibitors alongside insulin to improve outcomes.

Faculty

John Buse, MD, PhD
Verne S. Caviness Distinguished Professor
Director, Diabetes Center
Chief, Division of Endocrinology
Executive Associate Dean, Clinical Research
University of North Carolina School of Medicine
Chapel Hill, North Carolina


Anne L. Peters, MD
Director, USC Clinical Diabetes Program
Professor of Clinical Medicine
University of Southern California
Los Angeles, California


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. Integrity Continuing Education is committed to providing learners with high-quality CME/CE activities and related materials that promote improvement or quality in healthcare and not a specific proprietary business interest or a commercial interest.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

John Buse, MD, PhD
Consultant: Neurimmune AG
Research: Novo Nordisk, Sanofi, vTv Therapeutics
Ownership Interest: Mellitus Health, PhaseBio, Stability Health

Anne L. Peters, MD
Consultant: Abbott Diabetes Care, Becton Dickinson, Boehringer Ingelheim, Eli Lilly and Company, Lexicon, Livongo, Medscape, Merck, Novo Nordisk, OptumHealth, Sanofi
Speakers’ Bureaus: Novo Nordisk, Sanofi
Research: AstraZeneca, Dexcom, Mannkind
Stock Options: Mellitus Health, Omada Health, Stability Health

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.

Designation of Credit

Integrity Continuing Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of May 10, 2019 through May 10, 2020, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions about the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or information@integrityce.com.

Statement of Commercial Support

This activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals LP.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.